On Tuesday, UK regulators joined their US and European peers in approving an updated COVID-19 vaccine by Pfizer Inc (NYSE: PFE) and its German partner BioNTech (NASDAQ: BNTX) that targets only the Omicron XBB.1.5 subvariant. Moderna Inc (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) have also created the so-called monovalent versions of their shots that target the XBB.1.5 subvariant of the virus. XBB.1.5 was the most dominant variant across the globe earlier this year, which is why it was selected by regulators as the target for the updated version of coronavirus vaccines.Vaccine manufacturers continue to test the updated booster on newer variants, including the latest omicron sub-variant BA.2.86 that is raising concerns of infections across the globe.
While the U.S. expects to deploy all three ...